{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:53:37Z","timestamp":1778619217461,"version":"3.51.4"},"reference-count":21,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,14]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>First evidence of ruxolitinib efficacy for subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic lymphohistiocytosis. Supporting rationale for ruxolitinib use, not more aggressive treatment, in this context, questioning this condition\u2019s neoplastic nature.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001497","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T15:43:24Z","timestamp":1586447004000},"page":"1383-1387","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6393-0198","authenticated-orcid":false,"given":"Romain","family":"L\u00e9vy","sequence":"first","affiliation":[{"name":"Imagine Institute, Universit\u00e9 de Paris, INSERM U1163, Paris, France;"},{"name":"Unit\u00e9 d\u2019Immuno-Hematologie et Rhumatologie, D\u00e9partement de P\u00e9diatrie, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-3626","authenticated-orcid":false,"given":"Mathieu","family":"Fusaro","sequence":"first","affiliation":[{"name":"Imagine Institute, Universit\u00e9 de Paris, INSERM U1163, Paris, France;"},{"name":"Centre d\u2019Etude des Deficits Immunitaires, H\u00f4pital Necker-Enfants Malades, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Guerin","sequence":"first","affiliation":[{"name":"Imagine Institute, Universit\u00e9 de Paris, INSERM U1163, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Chetouani","sequence":"first","affiliation":[{"name":"M\u00e9decine Nucl\u00e9aire, Groupe Hospitalier Nord-Essone, Orsay, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despina","family":"Moshous","sequence":"first","affiliation":[{"name":"Imagine Institute, Universit\u00e9 de Paris, INSERM U1163, Paris, France;"},{"name":"Unit\u00e9 d\u2019Immuno-Hematologie et Rhumatologie, D\u00e9partement de P\u00e9diatrie, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Fischer","sequence":"first","affiliation":[{"name":"Imagine Institute, Universit\u00e9 de Paris, INSERM U1163, Paris, France;"},{"name":"Unit\u00e9 d\u2019Immuno-Hematologie et Rhumatologie, D\u00e9partement de P\u00e9diatrie, and"},{"name":"Coll\u00e8ge de France, Paris, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"de Saint Basile","sequence":"first","affiliation":[{"name":"Imagine Institute, Universit\u00e9 de Paris, INSERM U1163, Paris, France;"},{"name":"Centre d\u2019Etude des Deficits Immunitaires, H\u00f4pital Necker-Enfants Malades, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5865-4929","authenticated-orcid":false,"given":"Fernando E.","family":"Sepulveda","sequence":"first","affiliation":[{"name":"Imagine Institute, Universit\u00e9 de Paris, INSERM U1163, Paris, France;"},{"name":"Centre National de la Recherche Scientifique, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Neven","sequence":"first","affiliation":[{"name":"Imagine Institute, Universit\u00e9 de Paris, INSERM U1163, Paris, France;"},{"name":"Unit\u00e9 d\u2019Immuno-Hematologie et Rhumatologie, D\u00e9partement de P\u00e9diatrie, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"issue":"2","key":"2020040911380179400_B1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"issue":"20","key":"2020040911380179400_B2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020040911380179400_B3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.semdp.2016.11.009","article-title":"Cutaneous lymphomas with a panniculitic presentation","volume":"34","author":"Willemze","year":"2017","journal-title":"Semin Diagn Pathol"},{"issue":"7","key":"2020040911380179400_B4","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/pbc.24462","article-title":"Subcutaneous panniculitis-like T-cell lymphoma in the pediatric age group: a lymphoma of low malignant potential","volume":"60","author":"Huppmann","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2020040911380179400_B5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2340\/00015555-2543","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy","volume":"97","author":"Michonneau","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"2020040911380179400_B6","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41588-018-0251-4","article-title":"Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome [published correction appears in Nat Genet. 2019;51(1):196]","volume":"50","author":"Gayden","year":"2018","journal-title":"Nat Genet"},{"issue":"4","key":"2020040911380179400_B7","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/bloodadvances.2018028340","article-title":"Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma","volume":"3","author":"Polprasert","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"2020040911380179400_B8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2217\/fon.14.272","article-title":"Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis","volume":"11","author":"Arana Yi","year":"2015","journal-title":"Future Oncol"},{"issue":"5","key":"2020040911380179400_B9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"2020040911380179400_B10","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","volume":"127","author":"Das","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020040911380179400_B11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","article-title":"Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice","volume":"128","author":"Maschalidi","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2020040911380179400_B12","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"issue":"3","key":"2020040911380179400_B13","doi-asserted-by":"crossref","first-page":"e28071","DOI":"10.1002\/pbc.28071","article-title":"Successful remission induction in refractory familial hemophagocytic lymphohistiocytosis with ruxolitinib as a bridge to hematopoietic stem cell transplantation","volume":"67","author":"Ramanan","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"19","key":"2020040911380179400_B14","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/bloodadvances.2017007526","article-title":"Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis","volume":"1","author":"Broglie","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"2020040911380179400_B15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.hemonc.2017.07.002","article-title":"Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report","volume":"12","author":"Sin","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"2","key":"2020040911380179400_B16","doi-asserted-by":"crossref","first-page":"E47","DOI":"10.1002\/ajh.24971","article-title":"Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a single patient experience","volume":"93","author":"Slostad","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"2020040911380179400_B17","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1002\/ajh.25063","article-title":"Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a second experience","volume":"93","author":"Zandvakili","year":"2018","journal-title":"Am J Hematol"},{"key":"2020040911380179400_B18","article-title":"Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis [published online ahead of print 4 June 2019]","author":"Zhao","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2020040911380179400_B19","first-page":"73","article-title":"Refractory\/relapsed hemophagocytic lymphohistiocytosis treated with ruxolitinib: three cases report and literatures review [in Chinese]","volume":"40","author":"Wang","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"3","key":"2020040911380179400_B20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1365-2249.2003.02237.x","article-title":"Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis","volume":"133","author":"Takada","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"2020040911380179400_B21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2022008500","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1383\/1723459\/advancesadv2020001497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1383\/1723459\/advancesadv2020001497.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T15:43:36Z","timestamp":1586447016000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/7\/1383\/454297\/Efficacy-of-ruxolitinib-in-subcutaneous"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001497","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2022008500","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,9]]}}}